Rawi Hazzan1, InbalLasry Reish1, Mira Barak2, Rasha Daniel2, Merav Strauss3 and Eli Zuckerman4*
1Liver Unit, Emek Medical Center, Israel
2Haifa and Western Galilee Laboratories, Clalit Health Services, Israel
3Molecular Microbiology Laboratory, Emek Medical Center, Israel
4Liver Unit, Carmel Medical Center, Israel
Aim: Hepatitis C Virus (HCV) infection is one of the most prevalent etiologies for liver cirrhosis and hepatocellular carcinoma. HCV is highly heterogeneous, with seven confirmed major genotypes and 67 confirmed subtypes. The importance of determining correctly each genotype and its subtype lies in choosing appropriately the combination and duration of anti-viral treatment. The recombinant HCV genotype 2k/1b was first described in St. Petersburg in 2002 among intravenous drug users. Treatment of HCV 2k/1b patients with Sofosbuvir and ribavirin resulted in a low rate of Sustained Virologic Response (SVR). The high efficacy of the 3D regimen (Ombitasvir/paritaprevir/ritonavir and dasabuvir) has been proven for genotype1b population; however, it has not been evaluated for patients with 2k/1b HCV genotype. The aim of this study was to prospectively evaluate the efficacy and safety of twelve weeks treatment with Ombitasvir/paritaprevir/ritonavir and dasabuvir (3D) for patients infected with HCV 2k/1b.
Methods: This is an open-label, single arm study. Seven patients received Ombitasvir/paritaprevir/ ritonavir 25/150/100 mg once daily plus dasabuvir 250 mg twice daily for twelve weeks.
Results: Six patients achieved SVR without significant adverse events. One patient discontinued the treatment at week four due to headache and vomiting.
Conclusion: This study demonstrates that twelve weeks' treatment with Ombitasvir/paritaprevir/ ritonavir and dasabuvir (3D) of adult patients with HCV 2k/1b is highly efficient and safe.
Direct acting antiviral treatment; Genotype 2k/1b; Hepatitis C; Sustained virologic response
Hazzan R, Reish I, Barak M, Daniel R, Strauss M, Zuckerman E. Twelve Weeks Treatment with Ombitasvir/ Paritaprevir/Ritonavir and Dasabuvir in Chronic Hepatitis C Genotype 2k/1b Patients is Highly Efficient and Safe. Ann Clin Hepatol. 2019; 3(1): 1010.